An Open Label, Multicentre, Phase Ib/II Study of BGB324 (Bemcentinib) Administered as a Single Agent or in Combination with Cytarabine or Decitabine in Patients with Acute Myeloid Leukemia or as a Single Agent in Patients with Myelodysplastic Syndrome
MD Anderson Study Status
BGB324, Cytarabine, Decitabine
A Phase Ib/II multicentre open label study of BGb324 as a single agent in patients with AML or MDS or in a combination with cytarabine and decitabine in AML patients. BGB324 is a potent selective small molecule inhibitor of Axl, a surface membrane protein kinase receptor which is overexpressed in up to half of AML cases.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Acute Myeloid Leukemia, Myelodysplastic Syndromes
For general questions about clinical trials:
Help us #endcancer
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.